Asenapine review, part I: Chemistry, receptor affinity profile, pharmacokinetics and metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 6, 2014, Pages 893-903

  Citrome, Leslie ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b 11 Medical Park Drive ^*  (United States)

Author keywords

Antipsychotic; Asenapine; Metabolism; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ASENAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DOPAMINE; FLUVOXAMINE; GLUCURONOSYLTRANSFERASE 1A4; PAROXETINE; SEROTONIN; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

AREA UNDER THE CURVE; DEMETHYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ETHNICITY; GROUPS BY AGE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MOUTH MUCOSA; NONHUMAN; RECEPTOR AFFINITY; REVIEW; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; BIPOLAR DISORDER; CHEMISTRY; DRUG INTERACTION; METABOLISM; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; SCHIZOPHRENIA;

EID: 84901006230     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.908185     Document Type: Review

References (41)

1. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed secondgeneration antipsychotic. Int J Clin Pract 2009;63(12):1762-84
2. Merck & Co., Inc. Sahphris (asenapine) sublingual tablets. Prescribing information, revised March 2013. Available from: http://www.merck.com/ product/usa/picirculars/s/saphris/ saphrispi.pdf [Accessed 19 January 2014]
3. Citrome L. Asenapine review, part II: Clinical efficacy, safety and tolerability. Expert Opin Drug Saf 2014;13(6):803-30
4. US Food and Drug Administration. Asenapine Drug Approval Package. October 2, 2009, updated December 18, 2009. Available from: http://www. accessdata.fda.gov/drugsatfdadocs/nda/ 2009/022117s000TOC.cfm [Accessed 20 January 2014]
5. US Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. July 30, 2009. Available from: http://www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisory Committee/UCM173877.pdf [Accessed 26 January 2014]
6. Schering-Plough Research Institute. Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package). July 30, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf [Accessed 26 January 2014]
7. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10(12):1917-28
8. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27(11):879-911
9. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
10. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26(9):733-59
11. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient?s clinical profile. CNS Spectr 2004;9(10 Suppl 11):6-14
12. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012;25(2):96-102
13. Freedman R. a7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 2014;65:245-61
14. Stevenson R, Wolde HT. Update 4 - Akzo, Pfizer Scrap Asenapine Joint Development. November 28, 2006. Available from: http://www.reuters.com/ article/companyNewsAndPR/ idUSL286087420061128 [Accessed 19 January 2014]
15. Costall B, Domeney AM, Kelly ME, et al. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35(3):607-15
16. Forest Laboratories, Inc. Forest to acquire U.S. marketing rights to Saphris (asenapine) from Merck. Press release. December 2, 2013. Available from: http://news.frx.com/press-release/businessdevelopment- news/forest-acquire- usmarketing- rights-saphris-asenapine-merck [Accessed 19 January 2014]
17. Lundbeck. Lundbeck and Merck sign exclusive commercialisation agreement for Sycrest (asenapine) sublingual tablets in all markets outside of the United States, China and Japan. Press release. October 12, 2010. Available from: http://investor.lundbeck.com/releasedetail. cfm?ReleaseID=608583 [Accessed 19 January 2014]
18. Lundbeck. Sycrest 5mg and 10mg sublingual tablets. Summary of Product Characteristics. Last updated April 18, 2013. Available from: http://www. medicines.org.uk/emc/medicine/25632/ SPC/Sycrest+5mg+and+10mg+sublingual +tablets/ [Accessed 2 February 2014]
19. Funke CW, Hindriks H, Sam AP. Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 1990;40(5):536-9
20. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23(1):65-73
21. Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to noveltyseeking behavior. Neuroscience 2007;149(1):192-202
22. Frånberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196(3):417-29
23. Tarazi FI, Neill JC. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov 2013;8(1):93-103
24. Bartlett JA, van der Voort Maarschalk K. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS Pharm Sci Tech 2012;13(4):1110-15
25. Gerrits M, de Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos 2010;31(5-6):351-7
26. van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos 2011;39(4):580-90
27. Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet 2011;50(7):471-81
28. Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry 2012;27(5):472-82
29. Gerrits MG, de Greef R, Dogterom P, Peeters PA. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol 2012;52(5):757-65
30. Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 1997;131(4):339-45
31. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 2011;31(4):497-502
32. Sun X, Hamer R, McEvoy J. Once daily dosing improves asenapine effectiveness, patient acceptance and adherence as compared to twice daily dosing. Poster presentation II-87. NCDEU; May 28-31, 2013; Hollywood, Florida
33. Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 2014. [Epub ahead of print]
34. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
35. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
36. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30(2):106-15
37. Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72(3):349-55
38. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11(7):673-86
39. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebocontrolled trial. J Affect Disord 2010;122(1-2):27-38
40. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32(1):46-55
41. de Boer T, Meulman E, Meijering H, et al. Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. Biomed Chromatogr 2012;26(2):156-65